Name: Derm Decisions For Younger Children by Pharmaceutical Executive Magazine
Duration: 15 min 34 s
Description: In episode 118, Paula Brown Stafford, CEO of Novan, discusses the company’s upcoming NDA filing for its topical agent for molluscum contagiosum, what commercialization could look like and her goals for the future.

In episode 118, Paula Brown Stafford, CEO of Novan, discusses the company’s upcoming NDA filing for its topical agent for molluscum contagiosum, what commercialization could look like and her goals for the future.

Derm Decisions For Younger Children

In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Tom Fletcher, director of Research and Development at FUJIFILM Irvine Scientific; and Bob Newman, PhD, chief scientific director at FUJIFILM Irvine Scientific, about formulation, specifically with how to prepare culture media for use, single use technologies, and automations to create closed systems in cell/gene therapies.

Staying on Track with Formulation of Cell Culture Media

In this PC Podcast interview that originally aired for Pharmaceutical Executive, Camille Lee, UCB’s SVP and US head of immunology, dives into the history behind UCB's work in psoriasis;
the significance behind UCB announcing the commercial availability of Bimzelx for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy; how Bimzelx Navigate can be utilized as a resource for patients on this drug; and what listeners should keep an eye out for in terms of UCB's rheumatology pipeline.

Treating Psoriasis While Providing Patient Support

In this special episode of The Nutritional Outlook Podcast, we are interviewing the award winners of Nutritional Outlook’s 2023 Best of the Industry Awards, celebrating excellence, innovation, and leadership in the nutraceuticals and natural products industries. 

They are: Women in Nutraceuticals for Industry Leader, GenM for Service Provider, PLT Health Solutions for Ingredient Supplier.

Episode 28: 2023 Best of the Industry Award Winners

In this exclusive PC Podcast interview, Dave DeJean, Systech’s VP of global strategic accounts, dives into the valuable lessons he’s learned along the way, given his three and half decades of experience at Systech; an overview of the Drug Supply Chain Security Act (DSCSA), including its three main pillars; how he would interpret this “Stabilization Period” that the FDA provided this past summer, and what he pharma industry do now during this period in order to avoid penalties later; and whether or not he anticipates the FDA implementing any other sort of delays in the near future in order to help remedy these issues/challenges surrounding the enactment of DSCSA

Complying With the DSCSA

In this episode of the Drug Solutions Podcast, industry experts give an overview of the biosimilars market and discuss factors affecting not only their manufacture, but their upstake in the market as well.

The Biosimilars Landscape

In this episode, Nutritional Outlook interviews Scott Dicker, market insights director from market researcher SPINS, about ingredients and product categories nutraceutical and nutrition product manufacturers should watch in 2024. This interview complements our 2024 Ingredient to Watch coverage which can be read in our January/February issue.

Episode 29: 2024 Ingredients to Watch

In this exclusive PC Podcast interview, Rob Besse, Archbow Consulting’s VP of distribution services, shares a general overview of how the 3PL process works, using his 20-plus of pharma supply chain experience as added insight; the factors that manufacturers should consider when selecting a 3PL, along with the array of services that a quality 3PL should provide; valuable lessons he believes 3PLs learned during the COVID-19 pandemic that have helped improve efficiencies; and trends affecting the pharma industry that 3PLs be on the lookout for the rest of the year/

A First-Hand Account of 3PLs

Applying Appropriate Analytics to Drug Development

In this exclusive PC Podcast interview, Brandon Newman, Xevant’s CEO and founder, explores the implications of the Inflation Reduction Act’s price negotiation provisions, and how these could result in ripple effects across the healthcare system; the role that pharmacy benefit managers (PBMs) and other intermediaries' play when it comes to determining drug costs, and how spread pricing is involved; how Xevant helps improve drug cost transparency efforts; and strategies for affordability Newman would offer the pharma industry that can be implemented immediately.

A Further Examination of Pharmacy Benefit Managers

Rockstar Energy recently launched a new marketing campaign promoting its sustained mind body energy claim that has been substantiated through clinical research. Nutritional Outlook talks to Pepsi's vice president of North American Beverage R&D, Danielle Barbaro to discuss the study, why it was important for Rockstar Energy to conduct this study, and the value of fortifying energy drinks with nutraceuticals such as lion's mane.

Episode 30: Rockstar energy claim substantiation and use of nutraceutical ingredients

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.

Derm Decisions For Younger Children

Pharmaceutical Executive Magazine

Related tracks